Clinical TrialApr 22, 2026, 07:02 AM
BeyondSpring's Plinabulin Boosts ADC Efficacy & Survival in Preclinical Data
AI Summary
BeyondSpring Inc. reported new preclinical data at AACR 2026, showing Plinabulin significantly improves complete response rates and survival when combined with leading ADC drugs, both with and without immunotherapy. The data indicates Plinabulin enhances both efficacy and tolerability by activating GEF-H1, which matures immune cells, replenishes blood cells, and disrupts tumor blood supply. This strengthens the scientific rationale for Plinabulin's combination potential, extending its reach across the treatment landscape and supporting the planned DUBLIN-4 confirmatory Phase 3 trial.
Key Highlights
- Plinabulin improved complete tumor regressions and survival with ADCs T-DXd and Dato-DXd.
- Plinabulin reduced animal death in two-drug and three-drug combinations.
- Plinabulin enhanced CD8+ T cell/Treg ratio, activating the immune system.
- Plinabulin's GEF-H1 agonist mechanism is complementary to ADCs.
- DUBLIN-4 program, a 442-patient Phase 3 trial, is the next clinical step.
Price Impact
More from BYSI